Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis
Sep 08, 2022, 07:30 ET Study Designed to Evaluate the Safety, Tolerability, and Efficacy with PL8177 Oral Colon Delivery in Adult Subjects with Active Ulcerative Colitis Oral PL8177 May Provide a Safe and Tolerable Treatment Option for Ulcerative Colitis Patients CRANBURY, N.J., Sept. 8, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical […]